



September 15, 2015

Company name	3 - D M a t r i x , L t d .
A d d r e s s	3-2-4 Kojimachi, Chiyoda-ku, Tokyo
P r e s i d e n t	Kentaro Takamura
C o d e N u m b e r	7777
C o n t a c t	Director Tomoyuki Arai
T E L	+81 3 (3511)3440

**Patent Granted for “Transfection Agent (Agent for Transfer of Nucleic Acids into Cells)”
Using the 3D-Matrix Peptide Technology**

In regards to the surfactant peptide technology for which a patent application was jointly submitted by the company and Nippon Medical School, we hereby announce that a patent related to application of a transfection agent (agent for transfer of nucleic acids into cells) has been granted in United States.

[Title of Invention]	Transfection Agent
[Patent Number]	USP No. 9133484
[Patent rights holder]	Nippon Medical School, 3D-Matrix Ltd.

This patent is related to a method for using surfactant peptides as transfection agents for injection of nucleic acids into tumors, and shows that introduction of nucleic acids to tumorous cells using surfactant peptides is effective in suppressing gene expression. In relation to this field, Dr. Taizo Yoshida (Associate Professor, Nippon Medical School, Department of Neurosurgery) has published papers and made presentations at academic conferences related to treatment applications of surfactant peptide technology to brain tumors. In addition, the company is collaborating with the National Cancer Center and an investigator-initiated clinical trial for breast cancer patients using this technology has been started by the National Cancer Center Hospital.

In basic research related to the introduction of nucleic acids into cells, cationic transfection agents such as cationic polymers or cationic liposomes, etc., are widely used, but their toxicity in cells are well-known, and many studies are currently in progress into a transfection agent with low cell toxicity and a lesser burden on the patient, and that also can be expected to demonstrate good gene introduction efficiency and a higher treatment effectiveness on tumors. Because of its low cell toxicity, use of the surfactant peptide shown in this patent as a transfection agent positions it as one possible candidate for a gene introduction method with clinical uses in various tumor treatments, including brain cancer.

Utilizing this patent, the company will continue with research and development efforts and work to develop medical products, focusing on maximizing corporate value.

This announcement does not influence the earning forecast of the company at this moment. However, we will make necessary announcements when it is deemed that there is any influence.